PMID- 33165092
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 45
IP  - 4
DP  - 2021 Apr 1
TI  - MYB RNA In Situ Hybridization Facilitates Sensitive and Specific Diagnosis of 
      Adenoid Cystic Carcinoma Regardless of Translocation Status.
PG  - 488-497
LID - 10.1097/PAS.0000000000001616 [doi]
AB  - Adenoid cystic carcinoma (AdCC) can demonstrate histologic and 
      immunohistochemical (IHC) overlap with a wide range of salivary and nonsalivary 
      tumors, especially in small biopsy specimens. While MYB fluorescence in situ 
      hybridization (FISH) frequently is used to confirm the diagnosis of AdCC, the 
      pathognomonic MYB-NFIB fusion is only present in 40% to 70% of cases. Likewise, 
      although MYB RNA overexpression is seen in the vast majority of AdCC regardless 
      of translocation status, MYB IHC has shown suboptimal specificity for this 
      diagnosis. In this study, we sought to determine whether a novel chromogenic RNA 
      in situ hybridization (ISH) platform could directly detect MYB RNA overexpression 
      and offer a rapid diagnostic adjunct for AdCC. We performed MYB RNA ISH on 84 
      cases of AdCC as well as 128 other salivary tumors and 108 basaloid and sinonasal 
      carcinomas that mimic AdCC. MYB RNA ISH was 92% sensitive for AdCC, including 97% 
      of cases with MYB rearrangement and 83% without MYB rearrangement by FISH. It was 
      also 89% specific for AdCC overall, with 95% specificity among other salivary 
      tumors and 81% specificity in basaloid and sinonasal carcinomas. In contrast, MYB 
      IHC was 94% sensitive but just 54% specific for AdCC. Overall, MYB RNA ISH 
      provides superior sensitivity for the diagnosis of AdCC compared with MYB FISH 
      and superior specificity compared with MYB IHC. This assay could provide a useful 
      tool for rapidly confirming the diagnosis of AdCC in formalin-fixed, 
      paraffin-embedded specimens.
CI  - Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Rooper, Lisa M
AU  - Rooper LM
AD  - Departments of Pathology.
AD  - Oncology.
FAU - Lombardo, Kara A
AU  - Lombardo KA
AD  - Departments of Pathology.
AD  - Urology, The Johns Hopkins University School of Medicine, Baltimore, MD.
FAU - Oliai, Bahram R
AU  - Oliai BR
AD  - ProPath.
FAU - Ha, Patrick K
AU  - Ha PK
AD  - Department of Otolaryngology, University of California at San Francisco, San 
      Francisco, CA.
FAU - Bishop, Justin A
AU  - Bishop JA
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MYB protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myb)
RN  - 0 (RNA, Neoplasm)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Adenoid Cystic/*genetics/pathology
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - *In Situ Hybridization
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Proto-Oncogene Proteins c-myb/*genetics
MH  - RNA, Neoplasm/*genetics
MH  - Salivary Gland Neoplasms/*genetics/pathology
MH  - *Translocation, Genetic
MH  - Young Adult
COIS- Conflicts of Interest and Source of Funding: The authors have disclosed that they 
      have no significant relationships with, or financial interest in, any commercial 
      companies pertaining to this article.
EDAT- 2020/11/10 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/11/09 14:23
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2020/11/09 14:23 [entrez]
AID - 00000478-202104000-00005 [pii]
AID - 10.1097/PAS.0000000000001616 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2021 Apr 1;45(4):488-497. doi: 10.1097/PAS.0000000000001616.